G7 Therapeutics AG

G7 Therapeutics, a Swiss-based biotech company, develops novel medicines targeting the pharmaceutically highly relevant yet largely untapped superfamily of G protein-coupled receptors (GPCRs). G7 Therapeutics’ proprietary technology portfolio allows both the generation and removal of functional GPCRs from the complex cellular system for investigations on a molecular level. G7 Therapeutics’ technological superiorities (CHESS and SaBRE platform) ensure the timely and reliable creation of GPCRs with outstanding biophysical properties to meet the requirements for modern drug discovery and design. While entering dedicated development partnerships with pharmaceutical companies, G7 Therapeutics focuses on its own proprietary pipeline by unlocking GPCRs implicated in disease areas with distinct unmet medical needs.